SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will participate in the following upcoming investor conferences in March:
Cowen 44th Annual Health Care Conference
Monday, March 4, 2024, at 9:10 a.m. ET
Leerink Partners Global Biopharma Conference
Monday, March 11, 2024, at 1:20 p.m. ET
Barclays 26th Annual Global Healthcare Conference
Tuesday, March 12, 2024, at 2:05 p.m. ET
Live webcasts of the presentations will be accessible on the Investor page of Travere’s website at ir.travere.com/events-presentations. Replays will be available for up to 30 days following each event.
About Travere Therapeutics
At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.
Contact Info
Last Trade: | US$14.66 |
Daily Change: | 0.09 0.62 |
Daily Volume: | 376,535 |
Market Cap: | US$1.280B |
March 31, 2025 March 17, 2025 February 11, 2025 January 06, 2025 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load